II Ivivi Technologies, Inc.

Ivivi Technologies, Inc. (AMEX:II), a leader in non-invasive, electrotherapeutic technologies, announced today its �Call for Papers� for the second annual Science of Electroceuticals� Symposium (�SOE 2�). The event, set for November 9, 2007 in New York City, will bring together thought-leaders in the scientific discipline of Electroceuticals�, which utilizes highly-refined pulsed electromagnetic fields (�PEMF�) for researching the non-invasive treatment of numerous medical conditions and diseases. �A paradigm shift is occurring in the field of Electroceuticals�, the next frontier in pulsed electromagnetic field therapy and electrotherapeutics,� said Andre� DiMino, Vice Chairman and Co-CEO of Ivivi Technologies, a company dedicated to the field of electrotherapeutics and sponsor of the symposium. �Medicine is on the cusp of exploiting the relationship between the body�s electrochemistry and healing and this year�s conference will allow practitioners, researchers and clinicians the opportunity to focus on the clinical applications, laboratory evaluations and practical use of Electroceuticals�.� SOE 2 welcomes contributions from researchers in numerous fields and specialties, given the multidisciplinary and collaborative nature of this paradigm-shifting approach to non-invasive electrotherapeutic intervention. Papers for this year�s conference should be submitted by September 10, 2007 in Word (.doc) and/or Power Point (.ppt) files to SOE2@ivivitechnologies.com and include: topic heading, name, mailing address, telephone/fax numbers, and e-mail address. Regular Submission: (eight-page max) After review, on September 28, accepted regular submissions will be announced and invited to present on the SOE 2 main agenda. Regular submissions will be allocated eight pages in the proceedings. Abstract Submissions: (one-page max) After review, selected authors will be notified on September 28 of acceptance of papers and will be invited to present a poster. Abstract submissions will be allocated one page in the proceedings. For more information, visit: www.ivivitechnologies.com About Ivivi Technologies, Inc. Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi�s research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company�s Electroceuticals� have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders. Forward-Looking Statements This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the statements related to the preliminary data discussed above. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company�s limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company�s products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company�s intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company�s products and other risks detailed from time to time in the Company�s filings with the Securities and Exchange Commission, including the Company�s registration statement on Form SB-2. The Company assumes no obligation to update the information contained in this press release.